RESEARCH ARTICLE

Acute and chronic kidney disease in elderly patients with hip fracture: prevalence, risk factors and outcome with development and validation of a risk prediction model for acute kidney injury

Christine J. Porter1, Iain K. Moppett2,5†, Irene Juurlink3, Jessica Nightingale4, Christopher G. Moran4 and Mark A. J. Devonald1

Abstract

Background: Hip fracture is a common injury in older people with a high rate of postoperative morbidity and mortality. This patient group is also at high risk of acute kidney injury (AKI) and chronic kidney disease (CKD), but little is known of the impact of kidney disease on outcome following hip fracture.

Methods: An observational cohort of consecutive patients with hip fracture in a large UK secondary care hospital. Predictive modelling of outcomes using development and validation datasets. Inclusion: all patients admitted with hip fracture with sufficient serum creatinine measurements to define acute kidney injury. Main outcome measures – development of acute kidney injury during admission; mortality (in hospital, 30-365 day and to follow-up); length of hospital stay.

Results: Data were available for 2848 / 2959 consecutive admissions from 2007-2011; 776 (27.2%) male. Acute kidney injury occurs in 24%; development of acute kidney injury is independently associated with male sex (OR 1.48 (1.21 to 1.80), premorbid chronic kidney disease stage 3B or worse (OR 1.52 (1.19 to 1.93)), age (OR 3.4 (2.29 to 5.2) for >85 years) and greater than one major co-morbidities (OR 1.61 (1.34 to 1.93)). Acute kidney injury of any stage is associated with an increased hazard of death, and increased length of stay (Acute kidney injury: 19.1 (IQR 13 to 31) days; no acute kidney injury 15 (11 to 23) days). A simplified predictive model containing Age, CKD stage (3B-5), two or more comorbidities, and male sex had an area under the ROC curve of 0.63 (0.60 to 0.67).

Conclusions: Acute kidney injury following hip fracture is common and associated with worse outcome and greater hospital length of stay. With the number of people experiencing hip fracture predicted to rise, recognition of risk factors and optimal perioperative management of acute kidney injury will become even more important.

Keywords: Hip fracture, Acute kidney injury (AKI), KDIGO creatinine criteria, Hospital length of stay, Kidney function, Mortality, Postoperative AKI, Surgery, Surgical complication

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hip fractures are a common injury in the elderly in the United Kingdom [1] and worldwide [2]. These patients are at high risk for protracted length of stay, post-operative mortality and morbidity and reduction in quality of life [3]. Any patients who develop post-operative acute kidney injury (AKI) are also likely to have an increased length of stay and a greater likelihood of in hospital mortality and morbidity [4–9].

Little has been published on patients who have both problems, although The Scottish Intercollegiate Group hip fracture guidelines identified pre- and post-operative hydration and pre-admission renal dysfunction as areas requiring further attention and research [1]. Previous studies on hip fracture [10] and AKI [11] have provided patchy information based on admission serum creatinine (SCr) values or small populations. Current concepts in renal injury highlight increasing age, pre-existing chronic kidney disease, male gender, diabetes mellitus, heart failure and surgery as major risk factors for AKI [12–14]. However, in the hip fracture population, these may be relatively non-sensitive and non-specific risk factors since two thirds of these patients are aged over 80 and co-morbidity, including chronic kidney disease (CKD), is common at admission. Relatively small changes in SCr can predict or indeed define AKI. These changes may be missed or discounted in this population, particularly in the early stages of AKI. Although many underlying risk factors for AKI may not be modifiable in this cohort, an understanding of the risks of developing AKI, and the consequences for the patient, may be of use for the multidisciplinary team caring for these patients.

The aim of this study was to describe the renal morbidity of the hip fracture population and its association with short and long-term mortality and to identify key risk factors for AKI within this population. We also wished to use these data to develop and validate a risk prediction model for development of AKI following hip fracture.

Methods
Nottingham University Hospitals NHS Trust has two substantial clinical databases developed by the Departments of Trauma and Orthopaedic Surgery and Renal and Transplantation. The Nottingham Hip Fracture database has been described previously [15, 16] and contains prospectively collected, quality controlled dataset based on the Standardised Audit of Hip Fractures in Europe (SAHFE) process [17].

The NUH renal AKI database is the largest single centre AKI database in the United Kingdom. It was developed in parallel with the Nottingham AKI e-alert, an automated real-time electronic alerting system that uses algorithms based on internationally recognised SCr-based definitions of AKI [18]. The AKI database includes all adult patients admitted overnight to Nottingham University Hospitals.

Data were extracted from the Hip fracture and AKI databases in accordance with Caldicott principles. We identified completed hospital episodes between 01/04/2007 and 31/03/2011 where a patient was admitted following hip fracture and where sufficient serial serum creatinine measurements were available to allow identification and staging of AKI using the 2012 Kidney Diseases Improving Global Outcomes (KDIGO) classification [19]. The AKI database automatically excludes patients known to be receiving regular dialysis for end-stage renal disease and patients who die before an overnight admission.

The Nottingham Hip Fracture Score (NHFS) was calculated for all patients. The NHFS is essentially a weighted seven factor frailty score specific to hip fracture: Age; Cognitive function on admission (Abbreviated Mental Test Score [20] <7); not living at home; sex (male); haemoglobin < 100 g L$^{-1}$; previous malignancy; >1 comorbidity (stroke/transient ischaemic attack; cardiovascular disease; diabetes; previously diagnosed renal disease. It has previously been shown to predict 30-day post hip fracture mortality in the UK [21, 22] and internationally [23].

Basic patient characteristics recorded included: age; gender; ethnicity; and pre-admission renal function.

Definitions and calculation of kidney dysfunction
Acute Kidney Injury (AKI)
For AKI staging, two serum creatinine (SCr) values are required. The renal database algorithm uses pre-admission baseline SCr (defined as the average Scr from all values measured 7-365 days pre hospitalisation), and compares this with first in-hospital measured Scr (AKI stage at admission). If a pre admission baseline is not available then an estimated Scr (eSCr) is calculated assuming a theoretical estimated glomerular filtration rate (eGFR) of 75 ml/min/1.73 m$^2$ and using backward calculation of the Modification of Diet and Renal Disease (MDRD) [24] equation, as recommended by KDIGO.

Staging of AKI is revised throughout the admission after each new SCr result and the overall worst AKI stage is recorded as the final AKI stage for the hospital episode. Ideally urine output criteria for AKI definition would be used in addition to SCr criteria but these data are not routinely recorded electronically and urine output measurement is not reliable in non-catheterised or incontinent patients (Table 1).

Chronic kidney disease (CKD)
CKD stage was calculated in patients with an actual baseline and a post discharge SCr. Pre-admission CKD
stage was calculated using mean pre-admission SCr, age, gender and ethnicity. Post-discharge CKD was calculated using mean post-discharge SCr (measured between 90 and 365 days following discharge), age, gender and ethnicity.

**Post-operative outcomes**

Data were retrieved for: length of acute hospital stay; time to death (in hospital and post-discharge); postoperative admission to critical care; renal recovery (percentage change comparing 90-365 day post discharge SCr and pre-admission known baseline) and dialysis dependence (defined as attending dialysis clinic 90-365 days post discharge).

A minimum 90 day time frame for renal recovery is used to assess renal outcome post discharge, in accordance with the Kidney Disease Outcomes Quality Initiative guidelines which defines CKD as a persistent decline in kidney function lasting > 90 days [25], otherwise patients are defined as recovered renal function.

**Statistical methods**

Data were analysed using R statistical package [26]. Continuous variables are presented as mean (95% confidence interval) or median [inter-quartile range] as appropriate. Categorical variables are described as proportions of the cohort. Student’s t-test was used to compare parametric data and the Mann-Whitney U-test was used to compare non-parametric data. Group comparisons were by either two-by-two contingency table with Chi-squared analysis, Kruskal-Wallis or ANOVA for multiple groups. Two-tailed P-values were calculated and a value of less than 0.05 was considered significant.

**Modelling and prediction**

Multivariate analysis of factors predictive of development of AKI was performed.

Logistic regression was conducted using development of AKI as the outcome and using all predictors with p < 0.2 on univariate analysis. Backwards elimination was used to optimise Akaike’s Information Criterion. Sensitivity analyses of this modelling were conducted: using age as a continuous rather than a categorical variable; and imputing CKD stage 2 for those patients without a measured pre-admission SCr.

Hazard ratios (HR) for mortality, with associated 95% confidence intervals (CI) were derived from Cox proportional hazard models stratified by AKI severity (using no AKI as the reference) or pre-admission eGFR (average for 7-365 days pre admission) group (using eGFR >60 ml/min/1.73 m$^2$ as the reference) including age and sex as co-variates. Analyses were repeated using imputed CKD stage 2 (eGFR >60 ml/min/1.73 m$^2$) for all those patients without a baseline SCr.

**Predictive modelling**

The full dataset was split at random [27] into training and testing subsets (ratio 0.66:0.34) using development of AKI as a sampling variable. Predictive risk scoring models were created using logistic regression modelling of the training dataset [28] using the predictors identified in the association modelling. Models were created using only patients with known pre-admission SCr and using imputed CKD stage 2 (eGFR >60 ml/min/1.73 m$^2$) for all those patients without a baseline SCr. Model performance was assessed using Receiver Operating Characteristic (ROC) curves (ROC (discrimination) and Hosmer-Lemeshow tests (calibration). Confidence intervals for area under the ROC curve (AUROC) were calculated using DeLong’s method [29] and confidence intervals for test performance measures were calculated using Wilson’s method [30] and Koopman’s method [31] (Likelihood ratios). The modelling is reported in accordance with the TRIPOD statement [32].

A simplified score was created based on the predictive modelling and assessed for discrimination and calibration on the testing subset as above.

**Results**

We identified 2959 completed hospital episodes between 01/04/2007 and 31/03/2011, where a patient was admitted for hip fracture and sufficient serial SCr measurements were collected to allow presence or absence of AKI to be defined. The revised NHFS (11) was available in 96.2% (2848/2959). A valid SCr from the time period 7-365 days before admission was available for 2044/2848 patients (71.8%). Median (IQR [range]) follow-up was 691 (215 - 1119 [1 -2151]) days.

The distribution of NHFS was very similar to those previously reported [15, 16, 20, 33] with median (IQR) [range] of 4 (3-6) [0-10]. Of the 2848 individual hospital episodes, 683 patients (24%) developed AKI. These were divided into stage 1 (483/683 patients 70.7%), stage 2 (136/683 19.8%), and stage 3 (64/683 9.4%). Four patients required renal replacement therapy for AKI (1 from stage 2 and 3 from stage 3).

Tables 2 and 3 details patient characteristics and outcomes. Patients who developed AKI were older than those who did not (85 [78.6 to 89.8] vs 82.6 [75.2 to 87.9]...
Table 2  Characteristics and outcomes of included participants according to Acute Kidney Injury stage

| Characteristics                        | No AKI | All AKI | Stage 1 | Stage 2 | Stage 3 | P value No AKI vs. All AKI |
|----------------------------------------|--------|---------|---------|---------|---------|---------------------------|
| Median [IQR]                           | 2165   | 683     | 483     | 135     | 64      |                           |
| Number (proportion %)                  |        |         |         |         |         |                           |
| Age, years                             | 82.6   | 85.0    | 85.5    | 84.3    | 83.9    | <0.001                    |
|                                         | [75.2 to 87.9] | [78.6 to 89.8] | [78.6 to 89.9] | [78.5 to 89.6] | [77.4 to 88.9] |                           |
| Male                                   | 562    | 214     | 154     | 38      | 22      | <0.001                    |
|                                         | (26.0) | (31.3)  | (31.9)  | (27.9)  | (24.4)  |                           |
| Number (%) with known baseline SCr     | 1587   | 457     | 342     | 75      | 40      | 0.001                     |
|                                         | (73.3) | (66.9)  | (70.8)  | (55.0)  | (62.5)  |                           |
| Baseline eGFR mls/min/1.73 m²           | 64     | 57      | 57      | 63      | 58      | <0.001                    |
|                                         | [50 to 77] | [43 to 74] | [42 to 72] | [48 to 72] | [37 to 81] |                           |
| CKD stage >=3                          | 658/1587 | 243/457 | 186/342 | 36/75   | 21/40   | <0.001                    |
|                                         | (41.5) | (53.1)  | (54.3)  | (48)    | (52.5)  |                           |
| Diabetes                               | 266    | 127     | 84      | 28      | 15      | <0.0001                   |
|                                         | (12.3) | (18.6)  | (14.9)  | (20.7)  | (23.4)  |                           |
| Previous Stroke or TIA                 | 271    | 104     | 72      | 19      | 13      | 0.069                     |
|                                         | (11.9) | (15.2)  | (14.9)  | (14.1)  | (20.3)  |                           |
| Cardiovascular disease                 | 1157   | 438     | 301     | 92      | 45      | <0.0001                   |
|                                         | (52.8) | (64.1)  | (62.3)  | (68.1)  | (70.3)  |                           |
| Greater than one defined co-morbidity   | 658    | 301     | 205     | 61      | 35      | <0.0001                   |
|                                         | (30.3) | (44.1)  | (42.4)  | (45.2)  | (54.7)  |                           |
| Admission AMTS <7                      | 743    | 244     | 171     | 49      | 24      | 0.5                       |
|                                         | (34.3) | (35.7)  | (35.4)  | (36.3)  | (37.5)  |                           |
| Admission haemoglobin < 100 g L⁻¹      | 154    | 61      | 49      | 8       | 4       | 0.13                      |
|                                         | (7.1)  | (8.9)   | (10.1)  | (5.8)   | (6.3)   |                           |
| Not admitted from home                 | 441    | 90      | 32      | 9       | 131     | 0.51                      |
|                                         | (20.3) | (18.6)  | (23.5)  | (14)    | (19.2)  |                           |
| Nottingham Hip Fracture Score          | 4      | 5       | 5       | 5       | 5       | <0.0001                   |
|                                         | [3–5]  | [4–6]   | [4–6]   | [4–6]   | [4–6]   |                           |
| Nottingham Hip Fracture Score >= 4     | 1544   | 583     | 414     | 113     | 56      | <0.0001                   |
|                                         | (71.3) | (85.4)  | (83.1)  | (83.1)  | (87.5)  |                           |
| Nottingham Hip Fracture Score >= 5     | 1044   | 417     | 302     | 75      | 40      | <0.001                    |
|                                         | (48.2) | (61.1)  | (62.5)  | (66.4)  | (62.5)  |                           |

AKI: Acute Kidney Injury, AMTS: Abbreviated mental test score, eGFR: estimated glomerular filtration rate, SCr: Serum creatinine, CKD: Chronic kidney disease

Table 3  Outcomes of included participants according to Acute Kidney Injury stage

| Characteristics                        | No AKI | All AKI | Stage 1 | Stage 2 | Stage 3 | P value No AKI vs. All AKI |
|----------------------------------------|--------|---------|---------|---------|---------|---------------------------|
| Median [IQR]                           | 2165   | 683     | 483     | 135     | 64      |                           |
| Number (proportion %)                  |        |         |         |         |         |                           |
| Length of Stay, days                   | 15     | 19.1    | 19      | 20      | 20      | <0.001                    |
|                                         | [11–23]| [13–31] | [13–31] | [12.3 to 32.5] | [12–32] |                           |
| Part stay in critical care             | 40     | 41      | 16      | 11      | 14      | <0.001                    |
|                                         | (1.8)  | (6.0)   | (3.3)   | (8.1)   | (21.9)  |                           |
| Proportion admitted multiple times, all 4 yrs. | 1378   | 401     | 301     | 71      | 29      | 0.020                     |
|                                         | (63.6) | (58.7)  | (62.3)  | (52.2)  | (45.3)  |                           |
| In patient deaths                      | 134    | 169     | 100     | 39      | 30      | <0.001                    |
|                                         | (6.2)  | (24.7)  | (20.7)  | (28.7)  | (46.9)  |                           |
| 30-day mortality                       | 139    | 131     | 79      | 27      | 25      | <0.001                    |
|                                         | (6.4)  | (19.2)  | (16.4)  | (19.9)  | (39.1)  |                           |
| 1 year mortality                       | 534    | 305     | 203     | 61      | 41      | <0.001                    |
|                                         | (24.7) | (44.7)  | (42.0)  | (44.9)  | (64.1)  |                           |
years, \( p < 0.0001 \)). This was true for men (83.8 [74.9 to 88.5] vs 78.3 [66.5 to 85.7], \( p < 0.0001 \)) and women (86.0 [80.1 to 90.1] vs 83.8 [77.1 to 88.6] years, \( p < 0.0001 \)).

Patients with AKI were more likely to be male than those who were not (31.3% vs. 26%, \( p < 0.0001 \)). Length of stay was 15 [11 to 23] days for the no AKI group and 19 [13 to 31] days in those with AKI (\( p < 0.0001 \)). Use of a critical care bed post-operatively increased with increasing stage of AKI.

Table 2 details the univariate analysis of potential risk factors for development of AKI. Multivariate analysis with optimisation of AIC showed age, pre-existing CKD, sex and two or more co-morbidities to be independently predictive of development of AKI (Table 4, Fig. 1).

**Pre admission chronic kidney disease**

The risk of developing AKI, and its severity, were associated with pre-admission SCr and eGFR. For the 2044 patients with a documented pre-admission SCr, Table 4 shows the inverse relationship between pre-admission eGFR, incidence and severity of AKI and 30-day mortality. In the no AKI group 26.7% (578/2165) did not have a pre-admission SCr available, whilst in the AKI group (all stages) it was 33% (226/683). For each stage of AKI the proportions without a known pre-admission SCr were: stage 1 29.2% (141/483), stage 2 44.4% (60/135) and stage 3 37.5% (24/64).

Pre-admission baseline eGFR (n = 1946) was inversely associated with in-hospital mortality within the whole cohort: eGFR <30 ml/min/1.73 m\(^2\) – 32.9% in-hospital mortality (25/76); eGFR 30-60 ml/min/1.73 m\(^2\) – 12.4% (98/727) and eGFR >60 ml/min/1.73 m\(^2\) - 10.4% (119/1143).

**Survival following hip fracture**

Mortality as an inpatient, 30-days and one year was increased for those patients who developed AKI and those with pre-existing chronic kidney disease (Tables 3 and 5; Figs. 2 and 3).

**Table 4 Multivariate risk factors for development of Acute kidney injury during admission**

| Coefficients | OR (95% CI) | \( p \) |
|--------------|-------------|--------|
| Intercept    | -2.476      | <0.0001|
| Male sex     | 0.390       | 1.48 (1.21 to 1.80) | 0.0004|
| CKD stage 3B-5 | 0.417 | 1.52 (1.19 to 1.93) | 0.0008|
| Age 65 – 85 | 0.896       | 2.45 (1.66 to 3.74) | <0.0001|
| Age > 85    | 1.223       | 3.40 (2.29 to 5.20) | <0.0001|
| Two or more comorbidities | 0.475 | 1.61 (1.34 to 1.93) | <0.0001|

Patients without known Scr were imputed to CKD stage 2. The results for all predictors are almost identical if age is used as a continuous variable (OR 1.033 (1.024 to 1.043), \( p < 0.0001 \)).

Multivariate analysis identified age (continuous and categorised), male sex, pre-existing CKD \( \geq 3B \) and AMTS <7 as independent risk factors for 30-day mortality (Table 6). The results were trivially different whether imputed or unknown CKD stage was used (Fig. 4).

Cox proportional hazards modelling including all the elements of the Nottingham Hip Fracture Score, CKD stage and AKI grade identified age (65-85 years 2.4 (1.8-3.3); >85 years 4.0 (3.0 – 5.4)), male sex (all AKI grades, AMTS <7, residential status (all \( p < 0.0001 \)), haemoglobin < 100 g L\(^{-1}\), (\( p = 0.0003 \)), CKD stages \( \geq 3B \) (\( p = 0.003 \)) and >1 comorbidity (\( p = 0.0003 \)) as independent risk factors (Table 7).

**Survivors and renal outcome**

Of the 2545 survivors to hospital discharge, 48.2% (1227) had both a pre and post admission eGFR available. Incidence of any stage of AKI was 17.6% (216/1227) in this group.

Pre-admission and post-discharge eGFR were correlated for both no AKI and AKI groups (\( r^2 0.79 \) and \( r^2 0.82 \), \( p < 0.001 \) respectively). There was a statistically but not clinically significant improvement in renal function following discharge in the no AKI group (\( n = 1011 \)) (63 [50 to 77] ml/min/1.73 m\(^2\) vs. 67 [53 to 83] ml/min/1.73 m\(^2\) (\( p = 0.0002 \)). There was no change in the AKI group (\( n = 216 \)) (59 [47 to 77] l/min/1.73 m\(^2\) vs 60 [48 to 77] ml/min/1.73 m\(^2\) (\( p = 0.48 \)).

**Risk prediction models**

Two risk prediction models were developed using the training set and the previously identified predictors. The
patient characteristics and outcomes of the two groups were similar (Tables 8 and 9).

Model 1: Age (<65, 65-85, >85), CKD stage (3B-5), two or more comorbidities, sex (male)

Model 2: Age (continuous), CKD stage (3B-5), two or more comorbidities, sex (male)

A third model was tested using a simplified scoring system based on Model 1 (Table 10). The predicted risk from the new score is calculated as:

\[
\text{Predicted risk} = \frac{1}{1 + e^{(2.264 - [\text{NH-RISK}/4])}}
\]

Where NH-RISK is the sum of the individual scores

Areas under the ROC curves were 0.63 (0.59 to 0.67), 0.65 (0.61 to 0.69) and 0.63 (0.60 to 0.67) respectively. Calibration was adequate for all three models \((p = 0.464, 0.438 \text{ and } 0.847)\) (Table 11; Figs. 5 and 6).

**Discussion**

Our main findings are: first, AKI occurs in 1 in 4 hip fracture patients; second, mortality risk and acute length of stay increase with increasing severity of AKI; third, male sex, older age, pre-admission CKD and having more than one comorbidity are independent risk factors for AKI; and lastly, mortality risk post hip fracture is increased if pre-injury eGFR is <30 ml/min/1.73 m².

### Table 5: Acute kidney injury and mortality according to pre-admission estimated glomerular filtration rate

| Pre admission creatinine eGFR grouping | Number | AKI stage during admission Number (% of CKD group) | Mortality Number (%) |
|---------------------------------------|--------|---------------------------------------------------|----------------------|
|                                       |        | No AKI | Stage 1 | Stage 2 | Stage 3 | All AKI | 30 Day | One year |
| <15 ml/min/1.73 m²                    | 10     | 1 (10) | 3 (30) | 0 (0) | 6 (60) | 9 (90) | 5 (50) | 9 (90) |
| 15-29 ml/min/1.73 m²                  | 66     | 36 (54.5) | 25 (37.9) | 4 (6.1) | 1 (1.5) | 30 (45.4) | 19 (28.8) | 37 (56.1) |
| 30-44 ml/min/1.73 m²                  | 292    | 202 (69.2) | 72 (21.1) | 11 (14.7) | 7 (17.5) | 90 (19.7) | 46 (15.8) | 118 (40.4) |
| 45-59 ml/min/1.73 m²                  | 533    | 419 (26.4) | 86 (25.1) | 21 (28.0) | 7 (17.5) | 114 (25.0) | 50 (9.4) | 157 (29.4) |
| >60 ml/min/1.73 m²                    | 1143   | 929 (58.5) | 156 (45.6) | 39 (52.0) | 19 (47.5) | 214 (46.8) | 97 (8.5) | 350 (30.1) |
| Total                                 | 2044   | 1587 (100) | 342 (100) | 75 (100) | 40 (100) | 457 (100) | 217 (10.6) | 671 (32.8) |

**AKI** Acute Kidney Injury  
**eGFR** estimated glomerular filtration rate  
**CKD** Chronic kidney disease

![Fig. 2](image1.png)  
**Fig. 2** Kaplan Meier plot of cumulative probability of mortality day adjusted for age and gender and stratified for AKI severity

![Fig. 3](image2.png)  
**Fig. 3** Kaplan Meier plot of cumulative probability of mortality day adjusted for age and gender and stratified for CKD severity
The incidence of AKI in this large hip fracture population was 24%. This is greater than has previously been reported and is around twice as common as in the general surgical population [34]. White and colleagues [10] reported an incidence of 36.1% of patients whose estimated GFR on admission was < 60 ml/min/1.73 m², but were unable to comment on whether this was acute, chronic or both. Previous studies of AKI following hip fracture have used considerably smaller sample sizes (<200) and have reported AKI incidence at around 16% [11] using either Acute Kidney Injury Network (AKIN) [25] or RIFLE [35] classifications of AKI. Until the publication of the KDIGO guidelines in 2012 this has been a major source of inconsistency in the classification and reporting of AKI incidence. This study is the first to use this validated classification and uses a large population suggesting that incidence has been under-estimated previously. Increasing age and male gender have previously

| Table 6 Risk factors for thirty-day mortality identified using multivariate logistic regression |
|------------------------------------------------|
| Coefficient | OR (95% CI) | p       |
| Intercept    | -3.786       | <0.0001 |
| Male sex     | 1.050        | 2.86 (2.16 to 3.77) | <0.0001 |
| CKD stage > =3B | 0.717       | 2.05 (1.47 to 2.84) | <0.0001 |
| Age > 85     | 0.981        | 2.67 (1.29 to 6.48) | 0.0159 |
| Age >85      | 1.801        | 6.05 (2.94 to 14.66) | <0.0001 |
| AMTS <7      | 0.505        | 1.66 (1.26 to 2.17) | 0.0002 |
| AKI during admission | 1.008 | 2.74 (2.09 to 3.59) | <0.0001 |
| Two or more comorbidities | 0.383 | 1.47 (1.11 to 1.93) | 0.0067 |

Patients with no known baseline eGFR were assigned to CKD Stage 2. The results for all predictors are almost identical if age is used as a continuous variable (OR 1.069 (1.051 to 1.087); p <0.0001)

AKI Acute Kidney Injury
eGFR estimated glomerular filtration rate
CKD Chronic kidney disease
AMTS Abbreviated mental test score

| Table 7 Hazard ratios for mortality using Cox proportional hazards modelling |
|-------------------|
| Hazard Ratio (95% CI) | p |
| Age 65 - 85 | 2.4 (1.8 to 3.3) | <0.0001 |
| Age >85 | 4.0 (3.0 to 5.4) | <0.0001 |
| Male sex | 1.8 (1.6 to 2.1) | <0.0001 |
| AMTS <7 | 1.6 (1.4 to 1.8) | <0.0001 |
| Not admitted from home | 1.6 (1.4 to 1.8) | <0.0001 |
| Admission haemoglobin < 100 g L⁻¹ | 1.4 (1.2 to 1.8) | 0.0033 |
| Two or more comorbidities | 1.5 (1.3 to 1.6) | <0.0001 |
| Any AKI | 1.6 (1.4 to 1.8) | <0.0001 |
| CKD stage > =3B | 2.05 (1.47 to 2.84) | <0.0001 |

| Table 8 Comparison of training and testing datasets – patient characteristics |
|--------------------------------|
| Characteristics | Training set (N = 1880) | Testing set (N = 968) |
| Age, years | 82.9 | [75.5 to 88.3] | 83.7 | [76.8 to 88.6] |
| Male | 534 | (28.4) | 242 | (25.0) |
| Number (%), with known baseline SCr | 1352 | (71.9) | 692 | (71.5) |
| Baseline eGFR ml/min/1.73 m² | 63 | [50 to 78] | 61 | [48 to 75] |
| CKD stage > =3 | 583 | (43.1) | 318 | (46.0) |
| Diabetes | 261 | (13.9) | 132 | (13.6) |
| Not admitted from home | 234 | (12.4) | 131 | (13.5) |
| Cardiovascular disease | 1011 | (53.8) | 540 | (55.8) |
| Greater than one defined co-morbidity | 629 | (33.5) | 330 | (34.1) |
| Admission AMTS <7 | 619 | (32.9) | 368 | (38.0) |
| Admission haemoglobin < 100 g L⁻¹ | 538 | (28.6) | 314 | (32.4) |
| Not admitted from home | 363 | (19.3) | 209 | (21.6) |
| Nottingham Hip Fracture Score | 4 | (3–6) | 5 | (4–6) |
| Nottingham Hip Fracture Score > = 4 | 1389 | (73.9) | 738 | (76.2) |
| Nottingham Hip Fracture Score > = 5 | 908 | (48.3) | 513 | (53.0) |
been reported as being associated with poorer outcomes after hip fracture [30, 36]. A large meta-analysis incorporating 94 studies reported advancing age and male gender to be the two strongest predictors of mortality in hip fracture surgery patients [37]. We add to this knowledge with another large study. Both chronic kidney disease (CKD) and AKI are associated with greater and earlier mortality [38–41]. Patients with pre-admission eGFR <30 ml/min/1.73 m² had a relative risk of developing AKI of 2.4 compared with those with eGFR >30 ml/min/1.73 m², supporting data that suggest pre-existing CKD increases risk of AKI [34, 42, 43]. AKI was associated with an increase in mortality. Of note, stage 1 and 2 AKI appear to carry the same intermediate increase in risk. This would support the assertion that ‘mild’ derangement of renal function, which is commonly seen (around 1 in 5) in this elderly population, is not benign. All mortality rates (in-hospital, 30 day, 90 day and 1 year) increased with increasing severity of AKI and with lower pre-admission renal function, demonstrating the importance of identifying both AKI and CKD in the elderly.

This is a single centre study so our data may not be replicated elsewhere, and the inherent weaknesses of logistic regression modelling have been discussed by others [44]. However, outcomes following hip fracture in Nottingham are similar to elsewhere [16, 45] and the demographics of our hip fracture population are similar to the rest of the UK. The rates of CKD and AKI are similar to previous studies, bearing in mind the differences in methodology. The strength of our

Table 9 Comparison of training and testing datasets – patient characteristics

| Characteristics | Training set (N = 1880) | Testing set (N = 968) |
|-----------------|-------------------------|-----------------------|
| Length of Stay, days | 16 [12–25] | 15 [11–24] |
| Part stay in critical care | 54 (2.9) | 26 (2.7) |
| Proportion admitted multiple times, all 4 yrs. | 1161 (61.8) | 618 (63.8) |
| In patient deaths | 192 (10.2) | 111 (11.5) |
| 30-day mortality | 164 (8.7) | 106 (11.0) |
| 1 year mortality | 533 (28.4) | 306 (31.6) |
| AKI 0 | 1429 (76.0) | 736 (76.0) |
| AKI 1 | 320 (17.0) | 165 (16.8) |
| AKI 2 | 85 (4.5) | 51 (5.3) |
| AKI 3 | 46 (2.4) | 18 (1.9) |

Table 10 Prediction models characteristics

| Model | Model 2 | Nottingham Hip Fracture – Risk Score for Kidney Injury (NH-RISK) |
|-------|---------|---------------------------------------------------------------|
|       |         | Coefficients                                                  |
|       |         | Intercept -2.264 -3.78 -2.264                                 |
|       |         | Male sex 0.358 0.370 1                                        |
|       |         | CKD stage 3B-5 0.266 0.216 1                                   |
|       |         | Age (year) - 0.028 -                                          |
|       |         | Age 65 – 85 0.705 - 3                                         |
|       |         | Age > 85 1.023 - 4                                            |
|       |         | Two or more comorbidities 0.518 0.521 2                       |


cr is Chronic kidney disease

Fig. 5 Calibration plot for model 1. Data for the full dataset are shown in grey, for the training set in green and the testing set in blue. The area of the points is proportional to the number of cases in each group. The line represents the line of equality, where observed and predicted outcomes are equal.
study includes the use of two large prospectively collected clinical databases with almost complete data capture for the four-year period. We were able to estimate pre-injury renal function in 72% of participants, which allows us to diagnose AKI on admission blood tests. We were also able to determine post-discharge renal function. The use of calculated pre-admission SCr, assuming normal GFR where no documented result is available, may result in over-estimation of the incidence and stage of AKI. Nevertheless, the data presented here demonstrate clinically relevant outcomes: the survival curves for Stage 1 and stage 2 AKI are essentially identical, and worse than those with no AKI. We have not been able to identify a highly discriminating combination of predictor variables – the AUROC was relatively poor at around 0.63. However, calibration is reasonable, suggesting that either the full models, or the simplified 9-point NH-RISK may be useful tools for classifying risk of AKI on admission. Accurate assessment of risk is widely perceived to be a driver to improved management, though direct evidence of changes in clinical care and outcomes is lacking. We intend to trial the use of the simplified scoring system as part of our hip fracture admission criteria, in the first instance simply to flag those patients identified as highest risk of AKI who may benefit from specific clinical interventions.

CKD is both a risk factor for fracture [38] and associated with poorer outcome. It is tempting to be nihilistic and ascribe CKD as a fixed predictor of poor outcome. However, AKI is potentially preventable in some patients, so should be viewed as a possible target for intervention. Simple interventions such as avoidance of nephrotoxic drugs and correction of hypotension and hypovolaemia are important, yet easily overlooked. NSAIDs are usually avoidable, at least during the period of risk for AKI. Similarly, there are often alternatives to nephrotoxic antibiotics such as gentamicin but, if considered the antimicrobial of choice, nephrotoxicity can be reduced with meticulous monitoring of blood levels. Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers are commonly prescribed in the elderly and are not nephrotoxins per se. There is currently no clear evidence on when to discontinue these drug classes peri-operatively with respect to reducing risk of AKI. Current consensus suggests temporary discontinuation where AKI [14] or hypotension has developed. The risk of hypovolaemia may be reduced by limitation of starvation times and with intravenous fluid administration before and during surgery. Intraoperative stroke volume guided fluid studies are currently underpowered to demonstrate statistically significant changes in development of AKI [46, 47] and echocardiography studies [48] suggest that around 25% of patients are still hypovolaemic immediately prior to theatre. Patients arriving in theatre with urinary evidence of ‘dehydration’ [49] also have a worse outcome. Hypotension, relative or absolute, is very common intra-operatively, both with spinal and general anaesthesia [50].

Acute kidney injury is a costly disease with National Health Service (NHS) costs estimated to be between £434 million and £620 million per year [14]. The English hip fracture population is predicted to increase in size from around 70000 per year currently to around 90-100000 by 2033 [51]. The medical complexity of patients with hip fracture is also increasing in particular with increasing numbers of patients with cardiovascular and renal disease on admission [52]. The increased requirements for a critical care bed and longer hospital stay when AKI occurs add to this burden. Taken together this would suggest that hip fracture-related AKI is likely to have a significant and increasing financial burden in the near future.

Conclusions

CKD and AKI are common findings in elderly hip fracture patients. Both are independently associated with poor outcome – mortality, critical care use and length of acute hospital stay. They are probably markers of chronic and acute comorbidity rather than the direct cause of death themselves. When available, pre-injury SCr should be obtained to facilitate early detection of AKI. The optimal approach to preventing AKI in this population is not yet known, but close monitoring of fluid balance, avoidance of nephrotoxic drugs, appropriate adjustment of renally

Fig. 6 Calibration plot for the Nottingham Hip Fracture – Risk Score for Kidney Injury (NH-RISK). Data for the full dataset are shown in grey, for the training set in green and the testing set in blue. The area of the points is proportional to the number of cases in each group. The line represents the line of equality, where observed and predicted outcomes are equal.
excreted drugs and prompt treatment of sepsis would seem sensible in all peri-operative patients.

Abbreviations
ACE: Angiotensin converting enzyme; AIC: Akaike’s Information Criterion; AKI: Acute Kidney Injury; AKIN: Acute Kidney Injury Network; AMTS: Abbreviated Mental Test Score; CND: Chronic Kidney Disease; eGFR: Estimated glomerular filtration rate (mL/min/1.73 m²); IQR: Interquartile range; KDIGO: Kidney Diseases Improving Global Outcomes; MDRD: Modification of Diet in Renal Disease; NHFS: Nottingham Hip Fracture Score; NH-RISK: Nottingham Hip Fracture – Risk Score for Kidney Injury; NHS: National Health Service; NUH: Nottingham University Hospitals; RIFLE: Risk | Injury | Failure | Loss | End stage renal disease; ROC: Receiver Operating Characteristic; SAHFE: Standardised Audit of Hip Fractures in Europe (SAHFE); SCI: Serum Creatinine

Acknowledgements
None to declare.

Funding
The work received no external funding.

Availability of data and materials
No further data will be published as publication of more granular data outside the trust is not permitted.

Authors’ contributions
CP designed the data collection tools, cleaned and analysed the data, drafted and revised the paper. KM initiated the collaborative project, analysed data, drafted and revised the paper. He is guarantor. U designed the data collection tools, cleaned and analysed the data, and revised the paper. JN designed the data collection tools, cleaned and analysed the data, and revised the paper. CM initiated the collaborative project, drafted and revised the paper. MAJD initiated the collaborative project, analysed data, drafted and revised the paper. All authors read and approved the final manuscript.

Competing interests
All authors have completed the ICMJE uniform disclosure at www.icmje.org/coiDisclosure.pdf and declare: IKM is a member of the editorial board of the British Journal of Anaesthesia, he is part of the NICE standards setting group for CG124 (Fragility Hip Fracture); CGM is the NHS England National Clinical Director for Trauma and previously was co-chair of the National Hip Fracture Database; MAJD was a member of the Guideline Development Group for NICE CG169, Acute Kidney Injury; development of the NUH AKI database and the Nottingham AKI e-Alert were funded by Nottingham University Hospitals Charities (nephrology research fund); no other relationships or activities that could appear to have influenced the submitted work.

Consent for publication
No patient identifiable data are published.

Ethics approval and consent to participate
Data were extracted from the hip fracture and AKI databases in accordance with Caldicott principles and registered as audit / quality improvement projects with Nottingham University Hospitals NHS Trust.

Transparency
The lead author (IKM, the manuscript’s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Author details
1Renal and Transplant Unit, Nottingham University Hospitals NHS Trust, Nottingham NG5 1PB, UK. 2Anaesthesia and Critical Care, Division of Clinical Neuroscience, University of Nottingham, Nottingham NG7 2RD, UK. 3Information and Computer Technology, Nottingham University Hospitals NHS Trust, Nottingham, UK. 4Department of Orthopaedic Trauma, Nottingham University Hospitals NHS Trust, Nottingham, UK. 5Department of Anaesthesia, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK.

Received: 22 December 2015 Accepted: 4 January 2017
Published online: 14 January 2017

References
1. Scottish Intercollegiate Guidelines Group. Prevention and Management of hip fracture in older people. 2009. http://www.sign.ac.uk/pdf/sign111.pdf Accessed 9 Sep 2015.
2. Borgstrom F, Lekander I, Ivergard M, Strom O, Svedbom A, Alekna V, et al. The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)–quality of life during the first 4 months after fracture. Osteoporosis Int. 2013;24:811–23.
3. Griffin XL, Parsons N, Achten J, Fernandez M, Costa ML. Recovery of health-related quality of life in a UK hip fracture population: The Warwick Hip Trauma Evaluation – a prospective cohort study. Bone Joint J. 2015;97-B:837–22.
4. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med. 2006;34:1913–7.
5. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53:961–73.
6. Laffance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol. 2010;21:945–52.
7. Wald R, Quinn RR, Luo J, et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA. 2009;302:1179–85.
8. Ishani A, Xue JI, Himelfarb J, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20:223–8.
9. Bucaloiu ID, Kirkner HL, Norfolk ER, Hartle 2nd JE, Perkins RM. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury: Kidney Int. 2012;81:477–85.
10. White SM, Rashid N, Chaklada A. An analysis of renal dysfunction in 1511 patients with fractured neck of femur: the implications for peri-operative anaesthesia. Anaesthesia. 2009;64:1061–5.
11. Bennet SJ, Berry OM, Goddard J, Keating JF. Acute renal dysfunction following hip fracture. Injury. 2010;41:335–48.
12. Kheterpal S, Tremer KK, Englese MJ, O’Reilly M, Shanks AM, Fetterman DM, et al. Predictors of postoperative acute renal failure after noncardiac surgery in patients with previously normal renal function. Anesthesiology. 2007;107:892–902.
13. Kheterpal S, Tremer KK, Heung M, Rosenberg AL, Englese M, Shanks AM, et al. Development and validation of an acute kidney injury risk index for patients undergoing general surgery: Results from a national data set. Anesthesiology. 2009;110:505–15.
14. Acute Kidney Injury: Prevention, detection and management of acute kidney injury up to the point of renal replacement therapy NICE Guideline CG169. National Institute for Health and Care Excellence 2013. http://www.nice.org.uk/guidance/cg169 Accessed 9 Jan 2017.
15. Maxwell MJ, Moran CG, Moppett IK. Development and validation of a preoperative scoring system to predict 30 day mortality in patients undergoing hip fracture surgery. Br J Anaesth. 2008;101:511–7.
16. Moppett IK, Parker M, Griffiths R, Bowers T, White SM, Moran CG. Nottingham Hip Fracture Score: longitudinal and multi-assessment. Br J Anaesth. 2012;109:46–50.
17. Parker MJ, Currie CT, Mountain JA, Thorngren KG. Standardized audit of hip fracture in Europe (SAHFE). Hip Int. 1998;8:10–5.
18. Porter CJ, Juulsen L, Bisset LH, Bavakunji R, Mehta RL, Devonald MA. A real-time electronic alert to improve detection of acute kidney injury in a large teaching hospital. Nephrol Dial Transplant. 2014;29:1888–93.
19. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter Suppl. 2012;1:138.
20. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972;1:233–8.
21. Moppett IK, Willis MD, Moran CG, Sahota O. The Nottingham Hip Fracture Score as a predictor of early discharge following fractured neck of femur. Age Ageing. 2012;41:322–6.
22. Rushton PR, Reed NR, Pratt RK. Independent validation of the Nottingham hip fracture score and identification of regional variation in patient risk within England. Bone Joint J. 2015;97-B(1):100–3.
23. Karres J, Heesakkers NA, Ultee JM, Vrouenraets BC. Predicting 30-day mortality following hip fracture surgery: Evaluation of six risk prediction models. Injury. 2015;46:371–7.
24. Levey AS. Measurement of renal function in chronic renal disease. Kidney Int. 1990;38:167–84.
25. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warran DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
26. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. http://www.R-project.org/. Accessed 9 Jan 2017.
27. Kuhn M. Building predictive models in R using the caret package. J Stat Software. 2008;28:1–26.
28. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2014. http://www.R-project.org/. Accessed 9 Jan 2017.
29. Kuhn M. Building predictive models in R using the caret package. J Stat Software. 2008;28:1–26.
30. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209–12.
31. Koopman PAR. Confidence intervals for the ratio of two binomial proportions. Biometrics. 1988;44:837–45.
32. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209–12.
33. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209–12.
34. Grams ME, Sang Y, Coresh J, Ballew S, Matsushita K, Molnar MZ, et al. Acute kidney injury. Crit Care. 2007;11:R31.
35. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
36. Frost SA, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Excess mortality attributable to hip-fracture: a relative survival analysis. Bone. 2013;56:23–9.
37. Hsu CY. Yes, AKI truly leads to CKD. J Am Soc Nephrol. 2012;23:979–83.
38. Nitsch D, Mylne A, Roderick PJ, Smeeth L, Hubbard R, Fletcher A. Chronic kidney disease and hip fracture-related mortality in older people in the UK. Nephrol Dialysis Transplant. 2009;24:1539–44.
39. Moppett IK, Rowlands M, Mannings A, Moran CG, Wiles MD, The NOTTS Investigators. LiDCO-based fluid management in patients undergoing hip fracture surgery under spinal anaesthesia: A randomized trial and systematic review. Br J Anaesth. 2012;108:2239–43.
40. Anderson S, Eldadah B, Halter JB, et al. Acute kidney injury in older adults. J Am Soc Nephrol. 2011;22:28–38.
41. Anderson S, Eldadah B, Halter JB, et al. Acute kidney injury in older adults. J Am Soc Nephrol. 2011;22:28–38.
42. Collins GS, Reitman JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Ann Intern Med. 2015;162(1):55–63.
43. Collins GS, Reitman JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Ann Intern Med. 2015;162(1):55–63.
44. Austin PC, Tu JV. Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. J Clin Epidemiol. 2004;57:1138–46.
45. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C. IOF Working Group on Epidemiology and Quality of Life. A Systematic Review of hip fracture incidence and probability of fracture worldwide. Osteoporosis Int. 2012;23:2239–56.
46. Moppett IK, Rowlands M, Mannings A, Moran CG, Wiles MD, The NOTTS Investigators. LiDCO-based fluid management in patients undergoing hip fracture surgery under spinal anaesthesia: A randomized trial and systematic review. Br J Anaesth. 2012;108:2239–43.
47. Bartha E, Arfwedson C, Immel A, Fernlund ME, Andersson LE, Kalman S. Randomized controlled trial of goal-directed haemodynamic treatment in patients with proximal femoral fracture. Br J Anaesth. 2013;110:545–53.
48. Canty DJ, Royse CF, Kilpatrick D, Bowyer A, Royse AG. The impact on cardiac diagnosis and mortality of focused transthoracic echocardiography in hip fracture surgery patients with increased risk of cardiac disease: a retrospective cohort study. Anaesthesia. 2012;67:1202–9.
49. Ylinen-Tara S, Strasser U, Berg K, Zdolsek JH, Krook H, Hahn RG. Preoperative urine-specific gravity and the incidence of complications after hip fracture surgery: A prospective, observational study. Eur J Anaesthesiol. 2014;31:85–90.
50. White SM, Moppett IK, Griffiths R, et al. Secondary analysis of outcomes after 11,085 hip fracture operations from the prospective UK Anaesthesia Sprint Audit of Practice (ASP-2). Anaesthesia. 2016;71:506–14.